[23] Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell LymphomaJan 1, 2025·Z Mo,L Groocock,S Wood,D Jankeel,D Mendy,ER Watson,Y Kai,et al.· 0 min read PDFTypeJournal articlePublicationBlood Cancer DiscoverypublicationsLast updated on Jan 1, 2025 AuthorsZ MoAuthorsL GroocockAuthorsS WoodAuthorsD JankeelAuthorsD MendyAuthorsER WatsonAuthorsY KaiAuthorset al.← [24] Development of a novel Ikaros/Aiolos transcriptional signature and correlation with patient response in multiple myeloma patients treated with CELMoDs Apr 8, 2026[22] O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer Jul 1, 2024 →